JP2023554347A - 第ＸＩ因子および／または第ＸＩａ因子抗体に対する抗薬物抗体を検出するための方法 - Google Patents

第ＸＩ因子および／または第ＸＩａ因子抗体に対する抗薬物抗体を検出するための方法 Download PDF

Info

Publication number
JP2023554347A
JP2023554347A JP2023536045A JP2023536045A JP2023554347A JP 2023554347 A JP2023554347 A JP 2023554347A JP 2023536045 A JP2023536045 A JP 2023536045A JP 2023536045 A JP2023536045 A JP 2023536045A JP 2023554347 A JP2023554347 A JP 2023554347A
Authority
JP
Japan
Prior art keywords
seq
factor
chain variable
variable region
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023536045A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023554347A5 (https=
Inventor
デブラ エー． フリードホルム，
ダニエル エム． ブルームフィールド，
ロイストン ジェイ． グラスプール，
ジョナサン イー． フリーマン，
ヤセル クデル，
Original Assignee
アントス セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アントス セラピューティクス， インコーポレイテッド filed Critical アントス セラピューティクス， インコーポレイテッド
Publication of JP2023554347A publication Critical patent/JP2023554347A/ja
Publication of JP2023554347A5 publication Critical patent/JP2023554347A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96452—Factor XI (3.4.21.27)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2023536045A 2020-12-18 2021-12-17 第ＸＩ因子および／または第ＸＩａ因子抗体に対する抗薬物抗体を検出するための方法 Pending JP2023554347A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063127536P 2020-12-18 2020-12-18
US63/127,536 2020-12-18
PCT/US2021/064117 WO2022133263A1 (en) 2020-12-18 2021-12-17 Methods for the detection of anti-drug antibodies against factor xi and/or factor xia antibodies

Publications (2)

Publication Number Publication Date
JP2023554347A true JP2023554347A (ja) 2023-12-27
JP2023554347A5 JP2023554347A5 (https=) 2024-12-23

Family

ID=82059801

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023536045A Pending JP2023554347A (ja) 2020-12-18 2021-12-17 第ＸＩ因子および／または第ＸＩａ因子抗体に対する抗薬物抗体を検出するための方法

Country Status (19)

Country Link
US (1) US20240077497A1 (https=)
EP (1) EP4264278A4 (https=)
JP (1) JP2023554347A (https=)
KR (1) KR20230121120A (https=)
CN (1) CN116601491A (https=)
AR (1) AR124434A1 (https=)
AU (1) AU2021401421A1 (https=)
CA (1) CA3199482A1 (https=)
CL (1) CL2023001709A1 (https=)
CO (1) CO2023008150A2 (https=)
CR (1) CR20230313A (https=)
CU (1) CU20230031A7 (https=)
EC (1) ECSP23053645A (https=)
IL (1) IL302904A (https=)
JO (1) JOP20230137A1 (https=)
MX (1) MX2023007281A (https=)
PE (1) PE20231679A1 (https=)
TW (1) TW202242414A (https=)
WO (1) WO2022133263A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025523802A (ja) * 2022-07-13 2025-07-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 分析物を検出するための弱酸性免疫アッセイ

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018526976A (ja) * 2015-06-26 2018-09-20 ノバルティス アーゲー 第ｘｉ因子抗体および使用方法
US20200300852A1 (en) * 2017-11-29 2020-09-24 Hoffmann-La Roche Inc. Target interference suppressed anti-drug antibody assay

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3713965A1 (en) * 2017-11-22 2020-09-30 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
WO2020231992A1 (en) * 2019-05-13 2020-11-19 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018526976A (ja) * 2015-06-26 2018-09-20 ノバルティス アーゲー 第ｘｉ因子抗体および使用方法
US20200300852A1 (en) * 2017-11-29 2020-09-24 Hoffmann-La Roche Inc. Target interference suppressed anti-drug antibody assay

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"An Acid Dissociation Bridgung ELISA for Detection of Antibodies Directed against Therapeutic Protein", JOURNAL OF IMMUNOLOGICAL MTHODS, vol. Vol.304, No.1-2, JPN6025041796, 2005, pages 189 - 195, ISSN: 0005707683 *
CHRISTINA U. LORENTZ ET AL.: "Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagul", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, vol. 39, no. 4, JPN6025041795, 31 January 2019 (2019-01-31), pages 799 - 809, ISSN: 0005707680 *
ECL(ELECTROCHEMILUMINESCENCE)法による抗薬物抗体(ANTI-DRUG ANTIBODY, ADA)の測定, JPN6025041798, 6 October 2014 (2014-10-06), ISSN: 0005707681 *
UMA KAVITA ET AL.: "A systematic study of the effect of low pH acid treatment on anti-drug antibodies specific for a dom", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 448, JPN6025041797, 2017, pages 91 - 104, ISSN: 0005707682 *

Also Published As

Publication number Publication date
JOP20230137A1 (ar) 2023-06-14
ECSP23053645A (es) 2023-08-31
CL2023001709A1 (es) 2023-11-17
CU20230031A7 (es) 2024-02-07
WO2022133263A1 (en) 2022-06-23
TW202242414A (zh) 2022-11-01
CR20230313A (es) 2023-08-18
AU2021401421A1 (en) 2023-06-22
US20240077497A1 (en) 2024-03-07
IL302904A (en) 2023-07-01
EP4264278A4 (en) 2024-11-27
AR124434A1 (es) 2023-03-29
AU2021401421A9 (en) 2024-10-24
EP4264278A1 (en) 2023-10-25
CA3199482A1 (en) 2022-06-23
KR20230121120A (ko) 2023-08-17
CN116601491A (zh) 2023-08-15
MX2023007281A (es) 2023-09-04
CO2023008150A2 (es) 2023-06-30
PE20231679A1 (es) 2023-10-19

Similar Documents

Publication Publication Date Title
JP7823009B2 (ja) 第ｘｉ因子抗体および使用方法
US20250197522A1 (en) Methods of treatment with anti-factor xi/xia antibodies
JP2022528595A (ja) 抗ＦＸＩ／ＦＸＩａ抗体及びその使用
JP2020513757A (ja) 第ｘｉ因子抗体および使用方法
US20240077497A1 (en) Methods for the detection of anti-drug antibodies against factor xi and/or factor xia antibodies
EP4543434A2 (en) Combination therapies with an anti-factor xi/factor xia antibody
RU2847356C2 (ru) Антитела к фактору xi и способы их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241213

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250702

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250710

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251014

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260414